CD1

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Retrieved on: 
Thursday, October 19, 2023
Pharmacology, AACR, Mantle cell lymphoma, Data, CD1, European, Biology, MCL, Cancer, Therapy, BTK, American Association for Cancer Research, Patient, Cyclin D1, Pharmaceutical industry

NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that one of the Company’s scientific collaborators, Gaël Roué, Ph.D., from the Josep Carreras Leukaemia Research Institute, Spain, made a podium presentation during the European MCL Network Annual Meeting in Dublin, Ireland on October 7, 2023 regarding promising ongoing preclinical studies of narazaciclib, in combination with ibrutinib and other targeted therapies used in the treatment for mantle cell lymphoma.

Key Points: 
  • The biology of MCL is very interesting to Onconova because of the link to cyclin D1 (CD1) overexpression.
  • We believe this molecular feature could make MCL amenable to treatment combinations that include narazaciclib,” said Steven Fruchtman, M.D., President and CEO of Onconova.
  • Together, these data provide a foundation of support for using narazaciclib in MCL and other cyclin-dependent indications.
  • Data from the combination of narazaciclib and ibrutinib showed significant synergistic anti-tumor activity in both sensitive and ibrutinib-resistant MCL models.

BRIAN MAY + FRIENDS: "STAR FLEET PROJECT" Special 40th Anniversary Edition

Retrieved on: 
Thursday, June 1, 2023
Online, KMET, Bass, Blues Breakers with Eric Clapton, Freedom, Interview, Life, ALL, Palace Theater (Gary, Indiana), Friends, Half-speed mastering, CD1, The Beano, Eye, Electricity, Spine, July 14, The Palace, EVH, Let Me Out, Palace Theatre, Mermaid Avenue: The Complete Sessions, We Will Rock You, Palace, Record Plant, Gold, Starfleet, Humour, Sound, Record, Poster, LOS, The Brian May Band, Special edition, Film industry, Nightclub, Music, Cassette tape

LOS ANGELES, June 1, 2023 /PRNewswire/ -- When Queen took a break for the first part of 1983, Brian May put his time to good use. Waking up one morning in Los Angeles, he decided to phone a few friends and invite them to collaborate on some tracks in California's famous Record Plant studios. The resulting collaboration was a great success, and Brian would later mold the recordings into a unique mini-album, Brian May + Friends: Star Fleet Project.

Key Points: 
  • – Brian May
    LOS ANGELES, June 1, 2023 /PRNewswire/ -- When Queen took a break for the first part of 1983, Brian May put his time to good use.
  • The resulting collaboration was a great success, and Brian would later mold the recordings into a unique mini-album, Brian May + Friends: Star Fleet Project.
  • This third release in the "Brian May Gold Series" offers an extensively revisited and expanded box set edition of these legendary sessions.
  • Containing two CDs, one vinyl LP, and a vinyl single, as well as other collector's items, Brian May + Friends: Star Fleet Sessions will be launched as a Deluxe Edition box set, worldwide on July 14th.

Bunker Hill Announces Upsized and Improved $67 Million Financing Package to Enable Completion of the Mine Restart, Offtake Agreement

Retrieved on: 
Tuesday, May 23, 2023
Bridge loan, Bunker Hill, Minority, CD2, Quill, CSE, Zinc, MI, Metal, Bunker Hill Mine and Smelting Complex, Teck Resources, Line, CD1, CPG, Silver, Lead, Documentation, Royalty, National instrument, Mining, Engineering, LINK, CFO, TSX, RDA, News, Music, Oil, Security (finance), Cryptocurrency, Stream

TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (CSE: BNKR) (“Bunker Hill” or the “Company) is pleased to announce the execution of a non-binding term sheet outlining an upsized and improved $67 million non-dilutive project finance package with Sprott Private Resource Streaming & Royalty Corp (“Sprott Streaming”). All figures in this news release are in US dollars unless otherwise stated.

Key Points: 
  • Sam Ash, CEO, stated “We are excited to announce an upsized and improved project finance package that we expect to backstop the full financing of the Bunker Hill mine restart, materially strengthen our balance sheet and liquidity, and support our TSX-V application.
  • We are thrilled to have partnered with Sprott Streaming, who have demonstrated their commitment and support for the project each step of the way.
  • Including the previously funded $8 million Royalty Convertible Debenture, $6 million Series 1 Convertible Debenture (the “CD1”), and $15 million Series 2 Convertible Debenture (the “CD2”), Sprott Streaming’s total commitment to the Bunker Hill Mine restart would increase to $96 million.
  • Any agreement with a metal trader, in lieu of the Debt Facility, would be subject to approval by Teck and Sprott Streaming.

Akeso Therapeutics, Inc. Announces Appointment of Steven A. Porcelli, MD, to Scientific Advisor Board

Retrieved on: 
Tuesday, May 17, 2022
Department, Immunology, NKT, Hospital, Therapy, Brigham, Research, III, Albert Einstein College of Medicine, Technology, United States Air Force Scientific Advisory Board, Yale University, Harvard Medical School, Cancer, CAR, Columbia University, CD1, MD, GLOBE, Pharmaceutical industry, Vaccine, Medical device, Rheumatology, Microbiology

Dr. Porcelli is among the worlds leading experts in NKT cell biology and joins Akeso Therapeutics, Inc. in advising the companys research and development.

Key Points: 
  • Dr. Porcelli is among the worlds leading experts in NKT cell biology and joins Akeso Therapeutics, Inc. in advising the companys research and development.
  • Akeso Therapeutics, Inc. is operating in stealth mode and is focusing on developing chimeric antigen receptor (CAR) engineered off-the shelf allogeneic NKT cell therapies for cancer.
  • By leveraging its NKT cell expansion platform and two in-house patents, Akeso Therapeutics is advancing allogeneic type I and type III NKT cell therapeutics.
  • We are delighted that Dr. Porcelli has joined Akeso Therapeutics as Scientific Advisor, said Dr. Xianzheng (Jerry) Zhou, Founder and Chief Executive Officer of Akeso Therapeutics.

The Band's Classic Fourth Album, 'Cahoots,' Celebrated With Remixed, Remastered And Expanded 50th Anniversary Edition Releases

Retrieved on: 
Friday, October 22, 2021
Bootleg, The Band, R&B, Dolby Atmos, Chest Fever, Morrison, Woodstock, Carnival, Garth Hudson, Across the Great Divide, The W.S. Walcott Medicine Show, Gospel, Special edition, CD2, R, Apple of Sodom (song), Olympia Theatre, The Brown Album, Portrait, Rag Mama Rag, Genetic method, Four Tops, Horns, Loving You, Stevie, Blu-ray, Singing, Man, Stage fright, Billboard, Fearless, The Children (1984 film), The Hawks, Little Richard, Great Divide, Woodstock Playhouse, When I Paint My Masterpiece, Music, We Can Talk, Slippin' and Slidin', Bass, Olympia Theatre, Dublin, The Unfaithful Servant, Canadian National Exhibition, Life, Technology, CD, Reproduction, Music from Big Pink, Rock of Ages (The Band album), CD1, Life Is a Carnival, Time, The Night They Drove Old Dixie Down, Cassette tape

On December 10, Capitol/UMe will celebrate the 50th anniversary of The Band's classic fourth album, Cahoots, with an assembly of newly remixed, remastered and expanded 50th Anniversary Edition packages, including a multi-format Super Deluxe 2CD/Blu-ray/1LP/7-inch vinyl box set along with digital, 2CD, 180-gram half-speed-mastered black vinyl and limited-edition 180-gram black vinyl packages.

Key Points: 
  • On December 10, Capitol/UMe will celebrate the 50th anniversary of The Band's classic fourth album, Cahoots, with an assembly of newly remixed, remastered and expanded 50th Anniversary Edition packages, including a multi-format Super Deluxe 2CD/Blu-ray/1LP/7-inch vinyl box set along with digital, 2CD, 180-gram half-speed-mastered black vinyl and limited-edition 180-gram black vinyl packages.
  • All the Anniversary Edition releases were overseen by principal songwriter Robbie Robertson and sport a new stereo mix by Bob Clearmountain from the original multi-track masters.
  • As Clearmountain shares in the liners, "Robbie told me, 'Just think of the original mixes as rough mixes.
  • Cahoots peaked at #21 on Billboard, marking The Band's fourth consecutive Top 30 album appearance.

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

Retrieved on: 
Thursday, May 20, 2021
Geology, Earth sciences, Petrology, Communication, Forward-looking statement, CD1D, Lava, CD1

The data demonstrated that LAVA-051 exerted substantial antitumor activity against patient derived CLL, MM and AML cells that express CD1d.

Key Points: 
  • The data demonstrated that LAVA-051 exerted substantial antitumor activity against patient derived CLL, MM and AML cells that express CD1d.
  • Ed has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercialization.
  • These forward-looking statements are based on LAVA\xe2\x80\x99s expectations and assumptions as of the date of this press release.
  • LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\nThree Months Ended March 31,\n'

LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Health, Oncology, Clinical trials, Medical specialties, Branches of biology, Clinical medicine, Clusters of differentiation, Immunology, Tumors of the hematopoietic and lymphoid tissues, CD1, Leukemia, Chronic lymphocytic leukemia, Natural killer T cell, Acute myeloid leukemia, Myeloid leukemia

It is the first antibody-based compound targeting CD1d to activate both V9V2-T and type 1 NKT cells.

Key Points: 
  • It is the first antibody-based compound targeting CD1d to activate both V9V2-T and type 1 NKT cells.
  • LAVA-051 exerted substantial antitumor activity against patient derived acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells that express CD1d.
  • In addition, improved survival was observed in in vivo AML and MM mouse xenograft models treated with LAVA-051.
  • The companys lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021.